Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. (Q54336250)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

H Jiang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

L-P Xu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

D-H Liu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

K-Y Liu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

S-S Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

B Jiang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Q Jiang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

H Chen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Y-H Chen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

W Han

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

X-H Zhang

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Y Wang

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

J-Z Wang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

F-R Wang

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Y-Z Qin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Y-Y Lai

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

English

0 references

publication date

21 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1146-1154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25046218%20AND%20SRC:MED&resulttype=core&format=json

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

10 March 2020

cites work

1 reference

12 December 2020

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

12 December 2020

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

1 reference

12 December 2020

Standardized definitions of molecular response in chronic myeloid leukemia.

1 reference

12 December 2020

Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies

1 reference

12 December 2020

Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Tra

1 reference

12 December 2020

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

1 reference

12 December 2020

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation

1 reference

12 December 2020

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

12 December 2020

Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib

1 reference

12 December 2020

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.

1 reference

12 December 2020

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

1 reference

12 December 2020

Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation

1 reference

12 December 2020

Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.

1 reference

12 December 2020

Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.

1 reference

12 December 2020

Chronic myeloid leukemia

1 reference

12 December 2020

Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies

1 reference

12 December 2020

How I treat CML blast crisis

1 reference

12 December 2020

Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia

1 reference

12 December 2020

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

12 December 2020

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

12 December 2020

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

1 reference

12 December 2020

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

12 December 2020

Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study

1 reference

12 December 2020

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

1 reference

12 December 2020

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

1 reference

12 December 2020

HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase

1 reference

12 December 2020

Chronic myelogenous leukemia: biology and therapy

1 reference

12 December 2020

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

12 December 2020